Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Xceleron announces key board and executive appointments
Increasing demand from big pharma for greater R&D productivity


YORK, England, June 13, 2011 – XCELERON, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that Dr. David Roblin has been appointed to its Board of Directors in a non-Executive capacity and Dr. Stuart Best has joined the company as Senior Director Operations.

Dr. Roblin joins the Xceleron Board from Pfizer Global R&D where he was most recently Senior Vice President R&D, Research Head and Site Director. He has an outstanding track record of product innovation and leadership, bringing about business and technology changes to improve productivity in research and development. His experience crosses therapeutic areas within the spectrum of small and large molecule R&D.

Dr. Best joins Xceleron from Merck, Scotland where he was Head of Bioanalysis. Dr. Best’s career has been distinguished by his leadership in applying progressively sophisticated analytical technologies to this expanding and complex area of chemistry. Prior to Merck, Dr Best developed his reputation as an authority in the use of mass spectrometry in bioanalysis at Charles River (Inveresk).

Xceleron CEO Michael Butler commented: “These two new additions to our team come at an exciting time for the Company. In the last two years Xceleron has more than doubled its ‘top 20’ pharmaceutical clients and is increasingly being asked to provide supporting data for critical events and regulatory submissions. David Roblin is a hugely valuable addition to our Board, he understands the nature of the challenge that large pharma companies face and will help us to continue to meet that need. Stuart Best is a seasoned pharma manager with a deep understanding of pharmaceutical clients’ operational needs and recognised expertise in the application of novel analytical technologies in drug regulatory development.”

Dr. Roblin commented: ”This is a unique opportunity with Xceleron. The pharmaceutical industry urgently needs innovative solutions and Xceleron’s ability to increase R&D productivity is creating a lot of client interest. The crucial benefits that we enable are reduction in cycle time from lead optimization to Phase 1, reduced development costs in Phases 1 and 2 and a shift in attrition from Phase 2 to Phase 1, making success in Phase 2 more likely.”

About Xceleron
Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials.

Xceleron pioneered the use of human microtracer and AMS and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland. For company information, visit Xceleron at www.xceleron.com


Media Contact
Michael Butler
Tel +1 240 306 2050
Cell +1 240 477 3895


Publisher Contact Information:

Xceleron Ltd
+1 240 306 2050
-

Company profile of Xceleron Ltd
Past press releases of Xceleron Ltd.

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.